CRISPR editing approaches have been applied for the correction of common β-hemoglobinopathies, including sickle cell disease (SCD) [132, 133] and β-thalassemia disorders [134] as well as an immunodeficient disorder (chronic granulomatous disease) caused by defect in NADPH oxidase 2 (NOX2) protein [135]. The gene discussed is CYBB; the disease is sickle cell disease.